[1]程利 何勇勇通* 综述 唐亮 审校.鞘氨醇激酶在肿瘤中的作用[J].中国微创外科杂志,2015,15(9):840-845.
　Chen Li,He Yongyong,Tang Liang..Role of Sphingosine Kinase on Tumors[J].Chinese Journal of Minimally Invasive Surgery,2015,15(9):840-845.
点击复制

鞘氨醇激酶在肿瘤中的作用()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
15
期数:
2015年9期
页码:
840-845
栏目:
文献综述
出版日期:
2015-09-20

文章信息/Info

Title:
Role of Sphingosine Kinase on Tumors
作者:
程利 何勇勇通* 综述 唐亮 审校
（安徽省宣城市人民医院普外一科，宣城242000）
Author(s):
Chen Li;  He Yongyong;  Tang Liang.
Department of General Surgery Ward Ⅰ, Xuancheng People’s Hospital of Anhui, Xuancheng 242000, China
关键词:
鞘氨醇激酶; 恶性肿瘤
Keywords:
Sphingosine kinase; Malignant tumor
分类号:
R730.53
文献标志码:
A
摘要:
鞘氨醇激酶是一种癌基因，能够促进恶性肿瘤细胞生长和抑制其凋亡，抑制剂的使用能够使肿瘤细胞加速凋亡。高表达鞘氨醇激酶的恶性肿瘤患者有较短的生存期和较高的复发率，而低表达者患者生存期较长。鞘氨醇激酶抑制剂的使用可以提高患者生存率和降低复发率。鞘氨醇激酶是恶性肿瘤患者预后的有用指标，可以作为治疗恶性肿瘤患者的一个有效的靶点。本文对鞘氨醇激酶对恶性肿瘤患者预后的影响做一综述。
Abstract:
Sphingosine kinase (SPHK) is an oncogene promoting tumor cell growth and inhibiting apoptosis. Inhibitors of SPHK promote tumor cell apoptosis. Patients with higher SPHK expression have shorter overall survival time and higher recurrence rates, whereas those with lower SPHK expression survives longer. Inhibitors of SPHK can improve survival and reduce recurrence rates. SPHK is a useful marker for the prognosis of malignant tumors, and it could be an effective target for treating malignant tumors. This article is to investigate effects of SPHK on the prognosis in patients with malignant tumors.

参考文献/References:

[1]Zhang Y, Wang Y, Wan Z, et al. Sphingosine kinase 1 and cancer: a systematic review and metaanalysis. PLoS One, 2014, 9(2):e90362-e90373.
[2]Shi J, He YY, Sun JX, et al. The impact of sphingosine kinase 1 on the prognosis of hepatocellular carcinoma patients with portal vein tumor thrombus. Ann Hepatol,2015, 14(2):198-206.
[3]Qin Z, Dai L, TrilloTinoco J, et al. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHVassociated primary effusion lymphoma. Mol Cancer Ther,2014,13 (1):154-164.
[4]Olivera A, Kohama T, Tu Z, et al. Purification and characterization of rat kidney sphingosine kinase. J Biol Chem,1998,273(20):12576-12583.
[5]Hasan NM, Longacre MJ, Stoker SW, et al. Sphingosine kinase 1 knockdown reduces insulin synthesis and secretion in a rat insulinoma cell line. Arch Biochem Biophys,2012,518(1):23-30.
[6]Murakami M, Ito H, Hagiwara K, et al. Sphingosine kinase 1/S1P pathway involvement in the GDNFinduced GAP43 transcription. J Cell Biochem,2011,112(11):3449-3458.
[7]Berdyshev EV, Gorshkova I, Usatyuk P, et al. Intracellular S1P generation is essential for S1Pinduced motility of human lung endothelial cells: role of sphingosine kinase 1 and S1P lyase. PLoS One,2011,6(1):e16571-e16579.
[8]Ter Braak M, Claas RF, Hegen B, et al. Cis4methylsphingosine is a sphingosine1phosphate receptor modulator. Biochem Pharmacol,2011,81(5):617-625.
[9]AlJarallah A, Chen X, González L, et al. High density lipoprotein stimulated migration of macrophages depends on the scavenger receptor class B, type Ⅰ, PDZK1 and Akt1 and is blocked by sphingosine 1 phosphate receptor antagonists. PLoS One,2014,4(9):e106487e106496.
[10]Paugh BS, Bryan L, Paugh SW, et al.Interleukin1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. J Biol Chem,2009,284(6):3408-3417.
[11]Kapitonov D, Allegood JC, Mitchell C, et al. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res,2009,69(17):6915-6923.
[12]Aydin M, Downing K, Villegas G, et al. The sphingosine1phosphate pathway is upregulated in response to partial urethral obstruction in male rats and activates RhoA/Rhokinase signalling. BJU Int,2010,106(4):562-571.
[13]Van Brocklyn JR, Jackson CA, Pearl DK, et al. Sphingosine kinase1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol,2005,64(8):695-705.
[14]Marfe G, Di Stefano C, Gambacurta A, et al. Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinibresistant chronic myeloid leukemia cells. Exp Hematol,2011,39(6):653-665.
[15]Zhang H, Li W, Sun S, et al. Inhibition of sphingosine kinase 1 suppresses proliferation of glioma cells under hypoxia by attenuating activity of extracellular signalregulated kinase. Cell Prolif,2012,45(2):167-175.
[16]Nunes J, Naymark M, Sauer L, et al. Circulating sphingosine1phosphate and erythrocyte sphingosine kinase1 activity as novel biomarkers for early prostate cancer detection. Br J Cancer,2012,106(5):909-915.
[17]Cho SY, Lee HJ, Jeong SJ, et al. Sphingosine kinase 1 pathway is involved in melatonininduced HIF1alpha inactivation in hypoxic PC3 prostate cancer cells. J Pineal Res,2011(1),51:87-93.
[18]Shirai K, Kaneshiro T, Wada M, et al. A role of sphingosine kinase 1 in head and neck carcinogenesis. Cancer Prev Res,2011,4(3):454-462.
[19]Pan J, Tao YF, Zhou Z, et al. An novel role of sphingosine kinase1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. J Transl Med,2011,9(10):157-165.
[20]Li W, Yu CP, Xia JT, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res,2009,15(4):1393-1399.
[21]Liu G, Zheng H, Zhang Z, et al. Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy. BMC Cancer,2010,10(16):495-505.
[22]Ruckhberle E, Rody A, Engels K, et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance ofsphingosine kinase 1 in breast cancer. Breast Cancer Res Treat, 2008,112(1):41-52.
[23]Shida D, Fang X, Kordula T, et al. Crosstalk between LPA1 and epidermal growth factor receptors mediates upregulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res,2008,15(16):6569-6577.
[24]Cho SY, Cho S, Park E, et al. Coumestrol suppresses hypoxia inducible factor 1α by inhibiting ROS mediated sphingosine kinase 1 in hypoxic PC3 prostate cancer cells. Bioorg Med Chem Lett,2014,24(11):2560-2564.
[25]Tan SS, Khin LW, Wong L, et al. Sphingosine kinase 1 promotes malignant progression in colon cancer and independently predicts survival of patients with colon cancer by competing risk approach in South asian population. Clin Transl Gastroenterol,2014,5(10):e51-e57.
[26]Paugh SW, Paugh BS, Rahmani M, et al. A selective sphingosine kinase 1 inhibitor intergrates multiple molecular therapeutic targets in human leukemia. Blood, 2008, 112(4):1382-1391.
[27]Fuereder T, Hoeflmayer D, JaegerLansky A, et al. Sphingosine kinase 1 is a relevant molecular target in gastric cancer. Anticancer Drugs,2011,22(3):245-252.
[28]Ruckhberle E, Karn T, Denkert C, et al. Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer.J Cancer Res Clin Oncol, 2013, 139(10):1681-1689.
[29]Pchejetski D, Bohler T, Brizuela L, et al. FTY(fingolimod) sensitizes prostate cancer cells to radiothera hy by inhibition of sphingosine kinase1. Cancer Res, 2010,70(21):8651-8661.
[30]Kharel Y, Mathews TP, Gellett AM, et al. Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1phosphate. Biochem J,2011,440(3):345-353.
[31]Xiao M, Liu Y, Zou F, et al. Sensitization of human colon cancer cells to sodium butyrateinduced apoptosis by modulation of sphingosine kinase 2 and protein kinase D. Exp Cell Res,2012,318(1):43-52.
[32]Kariya Y, Kihara A, Ikeda M, et al. Products by the sphingosine kinase/sphingosine 1phosphate (S1P) lyase pathway but not S1P stimulate mitogenesis. Genes Cells,2005,10(6):605-615.

备注/Memo

备注/Memo:
*通讯作者，Email：heyongyong84@sina.com
更新日期/Last Update: 2016-01-04